Abstract:Purines could be converted into uric acid in the gut microenvironment, triggering metabolic diseases, especially gout, while the uric acid excretion is impaired. However, increasing uric acid excretion remains a challenge. In this study, we prepared a uricase‐containing intestine‐targeted explosive hydrogel microspheres via gas‐shearing microfluidics for mucosal immobilization of uricase, to realize gout inhibition through a novel transporter protein regulation pathway to accelerate the uric acid excretion for the first time. After oral administration of hydrogel microspheres, uricase could be controllably released in the intestine to hydrolyze uric acid preliminarily for hydrogen peroxide production. Once exposed in the intestinal specific catalase, hydrogen peroxide would further generate a local hyperoxic microenvironment beneficial for dopamine polymerization, thereby immobilizing uricase in intestinal mucosa finally. Through this cascade reaction, only a small amount of uricase is required for local immobilization to in‐situ up‐regulate uric acid transporter proteins of intestinal epithelial cells, excreting uric acid from the epithelial cells into the intestines to be excreted, lowering the systemic uric acid level. In vitro and in vivo studies confirmed the precisely intestinal delivery of dopamine and uricase through intestine‐targeted explosive microspheres. In vitro evaluation demonstrated that the uric acid level in human fecal samples from gout patients could be significantly reduced by up to 37% by the mimic mucosa‐immobilized uricase on the isolated porcine tissues. In vivo experiments in mouse hyperuricemia model and acute gouty arthritis model confirmed that microspheres could effectively accelerate intestinal uric acid excretion, effectively increasing fecal uric acid excretion by up to 27.6% and reducing blood uric acid by up to 71%. In addition, 16S ribosomal RNA sequencing showed that the microspheres optimized intestinal flora composition, with a significant increase in probiotic bacteria such as Akkermansia muciniphila and Verrucomicrobiales, and inhibited some common intestinal bacteria in gout patients such as Bacteroidetes, thereby improving intestinal homeostasis. In conclusion, we developed a unique inducing pathway via the small intestine mucosal layer in‐situ regulation to firstly realize an efficient uric acid intestinal excretion for gout therapy. This article is protected by copyright. All rights reserved

Core–shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management

Rapidly separating dissolving microneedles with sustained-release colchicine and stabilized uricase for simplified long-term gout management

Synthetic Biohybrids of Red Blood Cells and Cascaded‐Enzymes@ Metal–Organic Frameworks for Hyperuricemia Treatment

Transdermal delivery of iguratimod and colchicine ethosome by dissolving microneedle patch for the treatment of recurrent gout

Nanocapsules of Therapeutic Proteins with Enhanced Stability and Long Blood Circulation for Hyperuricemia Management

Uricase-Expressing Engineered Macrophages Alleviate Murine Hyperuricemia

Multimodal smart systems reprogramme macrophages and remove urate to treat gouty arthritis

A universal powder-laden crosslinked chitosan microneedle patch for high-dose controllable drug delivery

A Novel Methacryloyl Chitosan Hydrogel Microneedles Patch with Sustainable Drug Release Property for Effective Treatment of Psoriasis

A Novel Cascade Nanoreactor Integrating Two-Dimensional Pd-Ru Nanozyme, Uricase and Red Blood Cell Membrane for Highly Efficient Hyperuricemia Treatment

Hybrid Microneedle-Mediated Transdermal Delivery of Atorvastatin Calcium-Loaded Polymeric Micelles for Hyperlipidemia Therapy

Microneedle transdermal drug delivery as a candidate for the treatment of gouty arthritis: Material structure, design strategies and prospects

Bmk9 and Uricase Nanoparticle Complex for the Treatment of Gouty Arthritis and Uric Acid Nephropathy

Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout

Mild hyperthermia enhanced synergistic uric acid degradation and multiple ROS elimination for an effective acute gout therapy

Intestine‐targeted Explosive Hydrogel Microsphere Promotes Uric Acid Excretion for Gout Therapy

Ultrarapid‐Acting Microneedles for Immediate Delivery of Biotherapeutics

Atavistic strategy for the treatment of hyperuricemia via ionizable liposomal mRNA

Biomimetic Integrated Nanozyme for Flare and Recurrence of Gouty Arthritis

Self‐Healing Porous Microneedles Fabricated Via Cryogenic Micromoulding and Phase Separation for Efficient Loading and Sustained Delivery of Diverse Therapeutics

Binding uric acid: a pure chemical solution for the treatment of hyperuricemia